Dissertation (Ph.D.)--University of Toledo, 2007. / "In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences." Title from title page of PDF document. Bibliography: p. 70-78, p. 93, p. 132-140, p. 164-168, p. 194-221.

Thesis (Ph. D.)--University of Adelaide, Depts. of Psychology and Community Medicine, 1992. / Includes bibliographical references (leaves 217-238).

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 5 uppsatser.

Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 53-56).

No description available.

- / -

The aim of this study was to carry out experiments with maize (Zea mays) for the purpose of finding out the efficiency of phytoextraction of chosen pharmaceuticals from the nutrient solution. The plants were cultivated for three weeks in a sterile environment. Then was added a nutrient solution enriched with chosen benzodiazepines - diazepam, flunitrazepam, nitrazepam and bromazepam - in concentration 5-10 mg/L. The samples from each plant were taken every day (24 hours) and then were analyzed with HPLC/UV. The efficiency of phytoextraction was evaluated in two ways. The first one as an percentage of a decrease of the concentration of the pharmaceuticals in the solution with time, the second one as an amount of phytoextracted pharmaceutical in milligrames per gram of the plant matter. From the standpoint of the decrease of the concentration was as the most efficient measured the phytoextraction of nitrazepam (74,7 %), less efficient diazepam and bromazepam (55,2 %, respectively 53,9 %) and the least efficient flunitrazepam (38,0 %). When converted to the mass of the plant matter the most efficient was found the phytoextraction of bromazepam (0,08 mg of drug to 1 gram of plant matter), lower efficiency by bromazepam and diazepam (both 0,02 mg) and the lowest again by flunitrazepam (0,01 mg). key...

Abstract The association between antipsychotics and brain volume changes in schizophrenia is not clear. Previous imaging studies have not examined benzodiazepine use, though it has been linked to cognitive impairment. The aim of this thesis was to examine the association between long-term antipsychotic and benzodiazepine use and brain structures in schizophrenia. Based on a systematic review and meta-analysis of previous studies on long-term antipsychotic use and brain changes in schizophrenia, a higher antipsychotic exposure associated with parietal lobe decrease and basal ganglia increase. Previous data on the topic is very heterogenous and the overall number of studies is small (N=34). Most reported findings were non-significant. In the Northern Finland Birth Cohort 1966, 38 cases with schizophrenia spectrum disorder participated in the longitudinal study at the ages of 24 and 43. In the cross-sectional study, 44 cases with schizophrenia and 35 cases with affective psychoses participated at the age of 43. Structural brain MRI scans were acquired from all participants an data on antipsychotic and benzodiazepine dose was collected using medical records and interviews. Illness severity and antipsychotic/benzodiazepine dose were included as confounders in the analyses. Higher scan-interval antipsychotic dose associated to volume increase in lateral ventricles and higher benzodiazepine dose associated to volume decrease in the caudate nucleus during the 9-year follow-up. In the 43-year study, higher lifetime antipsychotic dose associated to smaller nucleus accumbens volume in schizophrenia. In comparison, higher lifetime benzodiazepine dose associated to larger volumes of total gray matter, cerebral gray matter, and thalamus in affective psychoses. In analyses without illness severity and other medication as confounders, there were several statistically significant associations. It seems that long-term antipsychotic use may associate to structural brain changes in schizophrenia and some associations may be confounded by symptoms and the use of benzodiazepines. These findings underline the importance of taking benzodiazepine use and other confounding factors into account when studying the effects of antipsychotics on the brain. Further studies should focus on how these findings relate to cognition and functioning. / Tiivistelmä Psykoosilääkityksen yhteys skitsofreniassa tapahtuviin aivomuutoksiin on epäselvä. Aiemmat kuvantamistutkimukset eivät ole tutkineet bentsodiatsepiinien käyttöä, vaikka niiden käyttö on yhdistetty heikompaan kognititioon. Tämän tutkimuksen tarkoituksena oli selvittää pitkäaikaisen psykoosi- ja bentsodiatsepiinlääkityksen yhteyttä aivojen rakenteisiin skitsofreniassa. Systemaattisen katsauksen ja meta-analyysin perusteella suurempi psykoosilääkeannos liittyi päälakilohkon tilavuuden pienenemiseen sekä tyvitumakkeiden koon kasvuun skitsofreniassa pitkäaikaisseurannoissa. Aikaisempi kirjallisuus on erittäin heterogeenistä ja tutkimusten kokonaismäärä on pieni (N=34). Suurin osa löydöksistä ei ollut tilastollisesti merkitseviä. Pohjois-Suomen syntymäkohortti 1966 aineistossa 38 skitsofreniaspektrin psykoosia sairastavaa henkilöä osallistui pitkittäistutkimukseen 34 vuoden ja 43 vuoden iässä. Poikkileikkaustutkimuksessa 44 skitsofreniaa ja 24 mielialapsykoosia sairastavaa henkilöä osallistui tutkimukseen 43 vuoden iässä. Pään rakenteellinen magneettikuvaus tehtiin kaikille osallistujille. Tiedot psykoosilääkkeiden ja bentsodiatsepiinien annoksista kerättiin sairauskertomusmerkinnöistä ja haastatteluista. Taudin vakavuus ja psykoosilääkkeiden/bentosidatsepiinien annos huomioitiin sekoittavina tekijöinä. Korkeampi psykoosilääkeannos liittyi aivokammioiden koon kasvuun ja korkeampi bentsodiatsepiiniannos häntätumakkeen koon pienenemiseen 9 vuoden seurannassa. Poikkileikkaustutkimuksessa korkeampi elinaikainen psykoosilääkeannos liittyi pienempään makaavan tumakkeen tilavuuteen skitsofreniassa. Mielialapsykooseissa korkeampi elinaikainen bentsodiatsepiiniannos liittyi suurempaan koko aivojen harmaan aineen, isoaivojen harmaan aineen ja talamuksen tilavuuteen. Kun sekoittavia tekijöitä ei otettu huomioon, tilastollisesti merkitseviä yhteyksiä löytyi useammilta aivoalueilta Tutkimuksen perusteella psykoosilääkkeiden pitkäaikaiskäyttö saattaa liittyä aivojen rakenteellisiin muutoksiin skitsofreniassa. Bentsodiatsepiinien käyttö ja oireet voivat toimia sekoittavina tekijöinä. Löydökset korostavat sekoittavien tekijöiden huomioimisen tärkeyttä tutkittaessa psykoosilääkkeiden vaikutuksia aivoihin. Tulevaisuudessa tutkimusten tulisi selvittää, miten löydökset liittyvät kognitioon ja toimintakykyyn.

Benzodiazepines are among the most prescribed compounds for anti-anxiety and are present in many toxicological screens. These drugs are also prominent in the commission of drug facilitated sexual assaults due their effects on the central nervous system. Due to their potency, a low dose of these compounds is often administered to victims; therefore, the target detection limit for these compounds in biological samples is 10 ng/mL. Currently these compounds are predominantly analyzed using immunoassay techniques; however more specific screening methods are needed. The goal of this dissertation was to develop a rapid, specific screening technique for benzodiazepines in urine samples utilizing surface-enhanced Raman spectroscopy (SERS), which has previously been shown be capable of to detect trace quantities of pharmaceutical compounds in aqueous solutions. Surface enhanced Raman spectroscopy has the advantage of overcoming the low sensitivity and fluorescence effects seen with conventional Raman spectroscopy. The spectra are obtained by applying an analyte onto a SERS-active metal substrate such as colloidal metal particles. SERS signals can be further increased with the addition of aggregate solutions. These agents cause the nanoparticles to amass and form hot-spots which increase the signal intensity. In this work, the colloidal particles are spherical gold nanoparticles in aqueous solution with an average size of approximately 30 nm. The optimum aggregating agent for the detection of benzodiazepines was determined to be 16.7 mM MgCl2, providing the highest signal intensities at the lowest drug concentrations with limits of detection between 0.5 and 127 ng/mL. A supported liquid extraction technique was utilized as a rapid clean extraction for benzodiazepines from urine at a pH of 5.0, allowing for clean extraction with limits of detection between 6 and 640 ng/mL. It was shown that at this pH other drugs that are prevalent in urine samples can be removed providing the selective detection of the benzodiazepine of interest. This technique has been shown to provide rapid (less than twenty minutes), sensitive, and specific detection of benzodiazepines at low concentrations in urine. It provides the forensic community with a sensitive and specific screening technique for the detection of benzodiazepines in drug facilitated assault cases.

The use of capillary electrophoresis (CE) has been restricted to applications having high sample concentrations because of its low sensitivity caused by small injection volumes and, when ultraviolet (UV) detection is used, the short optical path length. Sensitivity in CE can be improved by using more sensitive detection systems, or by preconcentration techniques which are based on chromatographic and/or electrophoretic principles. One of the promising strategies to improve sensitivity is solid phase extraction (SPE). Solid Phase Extraction utilizes high sample volumes and a variety of complex matrixes to facilitate trace detection. To increase the specificity of the SPE a selective solid phase must be chosen. Immunosorbents, which are a combination of an antibody and a solid support, have proven to be an excellent option because of high selectivity of the antibody. This thesis is an exploratory study of the application of immunosorbent-SPE combined with CE for trace concentration of benzodiazepines. This research describes the immobilization and performance evaluation of an immunosorbent prepared by immobilizing a benzodiazepine-specific antibody on aminopropyl silica. The binding capacity of the immunosorbent, measured as µg of benzodiazepine/ gram of immunosorbent, was 39 ± 10. The long term stability of the prepared immunosorbent has been improved by capping the remaining aminopropyl groups by reaction with acetic anhydride. The capped immunosorbent retained its binding capacity after several uses.